**Neda Hashemi, MD**

**University of New Mexico Comprehensive Cancer Center**

**Treatments for Advanced/Metastatic Prostate Cancer,**

**Updates and Future Direction**

**Abstract:** The treatment landscape of metastatic prostate cancer has changed significantly in the last decade. There have been several agents approved by the FDA, including chemotherapy, hormonal therapy, gnomically targeted therapy, and immunotherapy. Promising agents continue to emerge, such as Lu-PSMA-617, which is an investigational Prostate Specific Membrane Antigen-targeted radioligand therapy, that combines a targeting compound with a therapeutic radioisotope. The roles of the existing and emerging drugs as well as when to apply them will be reviewed.

**Bio:** Neda Hashemi, M.D. is a board-certified medical oncologist with the University of New Mexico Comprehensive Cancer Center (UNMCCC). A 2003 graduate from Iran University of Medical Sciences, Dr. Hashemi completed a fellowship in Neuro-oncology at the Cleveland Clinic in 2012. She then completed residency in Internal Medicine at the University of Texas Medical School at Houston in 2015, where she worked at multiple hospitals, including the MD Anderson Cancer Center. She completed fellowship in Hematology and Oncology at the Indiana University where she was recognized with the Young Investigator Award for her significant contributions to clinical and basic science research in genitourinary cancers. Dr. Hashemi joined UNMCCC in 2018 focused on taking care of patients with genitourinary cancers. She leads the multidisciplinary Genitourinary Clinical Research Program at UNMCCC and serves as a member in several national committees including the immuno-oncology committee of the Alliance for Clinical Trials in Oncology.